Physician

Peter C Kurniali, M.D.

According to 2025 Medicare claims, Peter Kurniali, M.D. (NPI: 1922236793) practices hematology/oncology in the Bismarck, ND market, with the plurality of this provider's patient population coming from Burleigh, ND. This provider's primary affiliated billing organization is SANFORD BISMARCK (NPI: 1811941172; TIN: 450226700) and primary practice location at 58501-4457. Kurniali is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604), Caravan Health ACO 50 LLC (ACO ID: A5160), and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Kurniali's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 627 traditional Medicare patients, billed 2,381 HCPCS/CPT codes, and received $197,247 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 2,065 prescription claims across 292 beneficiaries totaling $5,527,405 in drug costs, led by Revlimid (Lenalidomide). DME data shows 82 claims. Open Payments data shows 100 records totaling $1,908. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $28,111 to $197,247. Similarly, Part D prescription costs have risen steadily, from $83,608 to $5,527,405. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	122	412	$28,111
2016	247	1,011	$61,092
2017	307	1,671	$108,434
2018	432	2,222	$147,329
2019	517	2,438	$158,264
2020	490	2,011	$129,970
2021	562	2,202	$173,691
2022	562	1,976	$152,927
2023	590	1,988	$158,042
2024	627	2,381	$197,247

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	64	270	$83,608
2016	94	525	$284,784
2017	135	841	$1,090,747
2018	194	1,336	$2,858,672
2019	232	1,483	$2,828,140
2020	209	1,273	$2,075,006
2021	236	1,575	$3,180,095
2022	261	1,670	$3,479,325
2023	284	1,719	$3,089,875
2024	292	2,065	$5,527,405

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	57	$22,496
2017	N/R	56	$12,089
2018	N/R	N/R	N/R
2019	N/R	25	$395
2020	N/R	80	$4,806
2021	N/R	46	$2,539
2022	N/R	38	$1,129
2023	N/R	46	$1,081
2024	N/R	82	$2,810

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	63	72	$131
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	136	136	$125
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	195	469	$104
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	61	188	$90
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	500	1,375	$70

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	102	2,827	$1,626,128
Pomalyst	Pomalidomide	48	1,304	$1,007,456
Venclexta	Venetoclax	26	768	$321,037
Lenvima	Lenvatinib Mesylate	13	390	$307,507
Cabometyx	Cabozantinib S-Malate	15	450	$259,852

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8700	Temozolomide, oral, 5 mg	N	N/R	27	$1,738
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	37	$696
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	18	$376

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	100	$1,908	Tempus AI, Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Peter C. Kurniali, M.D.?

Tedicare shows public-source Medicare data for Peter C. Kurniali, M.D. (NPI 1922236793), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Peter C. Kurniali, M.D. have ACO affiliation data?

Peter C. Kurniali, M.D. is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604), Caravan Health ACO 50 LLC (MSSP, ACO ID A5160), and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Peter C. Kurniali, M.D.?

Peter C. Kurniali, M.D. is linked to SANFORD BISMARCK (billing NPI 1811941172) in the available physician profile data.

Does Peter C. Kurniali, M.D. have Open Payments data?

Peter C. Kurniali, M.D. has 100 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.